IVD Technology

May/June 1999
Selected Contents

Editor's Page

Business smarts

COVER STORY:

Lateral-flow assays: Designing for automation
by David L. Carlberg

Low-tech assembly may dominate the world of IVD test strips today—but the companies that will flourish in the future are those that plan ahead for automation.

Troubleshooting protein binding in nitrocellulose membranes: Part 2: Common problems
by Kevin D. Jones

Manufacturers can ensure good protein binding results if they perform carefully designed and controlled experiments during product development.

Regulations and standards:
Point-of-care IVDs: Overcoming the hurdles to market
by Thomas M. Tsakeris

There are many reasons for the substantial growth of POC testing, but perhaps the most significant is that the accuracy and reliability of POC tests now approaches that of high-volume analyzers used in clinical laboratories.

Increasing antibody production with hollow-fiber bioreactors
By Yuan Shi, Julie Ploof, and Alberto Correia

Using a conditioned growth medium can give hollow-fiber bioreactors a head start toward higher yields at significantly reduced costs.

News Update:

French agency forces recall and replacement of glucose monitors
Several large glucose monitor companies recently felt the sting of the French Medicines Agency when their products were pulled off the market in what could be considered the European equivalent of a "voluntary" recall.

More tools for Alzheimer's diagnosis on the way
Although the field is wide open for companies working on accurate biochemical technologies for early diagnosis of AD, progress has so far been slow.

Applied Spectral Imaging receives color karyotyping patents
Over the past 10 months, the US Patent and Trademark Office has issued a series of patents for the color karyotyping technologies of Applied Spectral Imaging.

Competition abounds, but an IVD for early breast cancer detection is still remote
Mammography has been the gold standard for early detection of breast cancer since the 1960s. But mammography still has a false negative rate between 10% and 25%.